Building capability in-house is a reasonable default, and for extrusion, braiding and tip forming it is usually the right one. Surface chemistry behaves differently. It needs different equipment, different analytical methods and different people, and the development chain runs from formulation through substrate adhesion, process window, sterilization compatibility, shelf life and biological evaluation before you reach verification on the finished device. Each link has to close before the next one starts. Our platform enters that chain with the ISO 10993-1 program already passed and a coated central venous catheter already approved by the Taiwan FDA, so a project begins at substrate compatibility rather than at formulation.

No. Three kinds of intellectual property sit in a coated catheter and they stay separate. Your device IP, meaning your geometry, materials, construction, indications and clinical evidence, remains entirely yours. Our platform IP remains ours and is licensed to you for the application we agree on. Anything the two of us create during a joint program is defined in the agreement before the work starts rather than argued about afterwards. We appear in your technical documentation as the supplier of a device component, in the same way your resin and packaging suppliers do.

This is why technology transfer is one of the three routes rather than an afterthought. The coating is applied by single-step dip coating at ambient temperature, with no curing step, no UV and no proprietary equipment, so the process can run inside your own line under your own quality system and operated by your own people. Once it has been transferred, what you source from us is the formulation rather than the capability. For programs where continuity has to be secured contractually, we are open to the arrangements a procurement team would normally ask for.

It is a passive phospholipid bilayer that delivers hydrophilic and anti-fouling behavior from the same 5 nanometer layer. It is not an antimicrobial coating in the conventional sense. Antimicrobial coatings act on organisms by releasing or presenting a biocide; LipoCoat contains no antibiotics and no biocides. Its hydration layer keeps proteins, platelets and bacteria from adhering in the first place, which is also why it is non-thrombogenic and reduces hemolysis, platelet activation and protein adsorption including fibrinogen and albumin. Nothing depletes and nothing leaches, so performance does not decline across the dwell time and there is no mechanism through which bacterial resistance can develop.

Compatible polymers include polyurethane, PVC, silicone, PEBAX, PEEK and nylon. Device types include central venous catheters, peripherally inserted central catheters, other central vascular access devices, Foley and urological catheters, and vascular access sheaths. Catheters are one of our two proven application areas: a coated antifouling central venous catheter developed with CEMMA Medical and Eline Medical received Taiwan FDA approval in May 2025, with European and North American filings in preparation. For device types outside that set we start with a feasibility study rather than a promise.

Yes, and that combination is why most conversations start. SonoCoat® provides acoustic visibility during placement, LipoCoat® provides anti-fouling and lubricity across the dwell time, and the two are applied as a base layer and a top layer within one development program and one quality system. They are two platform technologies developed in house rather than two settings of one coating. LipoCoat® is in a device approved by the Taiwan FDA. SonoCoat® is not yet on the market; performance data is available on request.